The MAGE-A genes encode antigens that are of particular interest for antitumor immunotherapy because they are strictly tumor specific and are shared by many tumors. We developed a rapid method to identify the MAGE-A genes expressed in tumors. Methods: A low-density DNA microarray was designed to discriminate between the 12 MAGE-A cDNAs amplified by PCR with only one pair of consensus primers. The assay involved reverse transcription of total RNA with oligo(dT) primer, followed by PCR amplification and hybridization on a microarray. Amplification in the presence of Biotin-16-dUTP allowed subsequent detection of the amplicons on the microarray carrying 12 capture probes, each being specific for a MAGE-A gene. Probe-amplicon hybrids were detected by a streptavidin-based method. Results: PCR conditions were optimized for low detection limits and comparable amplification efficiencies among all MAGE-A nucleotide sequences. The microarray assay was validated with a panel of 32 samples, by comparison with well-established reverse transcription-PCR assays relying on amplification with primers specific for each gene. Virtually identical results were obtained with both methods, except for MAGE-A3 and MAGE-A5. Detection of MAGE-A5 was more sensitive with the microarray assay. Detection of MAGE-A3 was hampered by the presence of MAGE-A6, which is 98% identical: the MAGE-A3 capture probe cross-hybridized with MAGE-A6 amplicons because these sequences differed by only a single base.
The MAGE genes were initially identified because they encode tumor antigens that can be recognized by cytolytic T lymphocytes derived from blood lymphocytes of cancer patients (1 ) . The MAGE gene family is composed of 23 related genes divided into four clusters located in regions q28 (MAGE-A genes), p21.3 (MAGE-B genes), q26 (MAGE-C genes), and p11 (MAGE-D genes) of the X chromosome (2) (3) (4) (5) (6) (7) (8) (9) . MAGE-A, -B, and -C genes are expressed in various types of tumors, but not in healthy tissues, with the exception of testis and placenta. Unlike the other MAGE genes, MAGE-D genes are expressed ubiquitously.
The MAGE-A subfamily comprises 12 genes that share 60 -98% identity in their coding sequence, located entirely in the last exon. They encode proteins of 300 -370 amino acids (2 ) . Seven MAGE-A genes (MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12) were found to be highly transcribed in a large proportion of tumors of various histologic origins [for a review, see Ref. (10 ) ]. The five other MAGE-A genes are either not expressed in tumors (such as the MAGE-A7 pseudogene) or are expressed in very small amounts. However, MAGE-A8 and -A11 were found to be highly expressed in a small number of tumors (2, 11 ) . Many antigenic peptides presented to CD8 ϩ cytolytic T lymphocytes by HLA class I molecules have been identified in proteins MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 [for a review, see Ref. (10 ) ]. MAGE-A1 and -A3 peptides were also reported to be recognized on HLA class II molecules by CD4 ϩ T lymphocytes (12) (13) (14) (15) . The MAGE-A antigens are of particular interest for antitumor immunotherapy because they are strictly tumor specific and are shared by many tumors. The lack of expression of the encoding genes in healthy tissues should ensure strict tumoral specificity of immune responses obtained after vaccination of patients with these antigens. No adverse side effects are expected in testis because HLA molecules are not present at the surface of germline cells, the subset of testis cells expressing MAGE-A genes (16, 17 ) . These antigens are good candidates for immunization of a large number of patients because the encoding genes are expressed in a wide range of tumors.
Clinical trials have been initiated with MAGE-A-derived immunogens. In one of these trials, 25 tumorbearing HLA-A1 melanoma patients were immunized with a MAGE-A3 peptide presented by HLA-A1; objective regressions of metastases were observed in 7 patients. Three of these regressions were complete (18 ) .
The patients eligible for immunization with a defined MAGE-A antigen are those who have a tumor that expresses the relevant MAGE-A gene along with the appropriate HLA specificity. Whether these conditions are met can be tested readily by HLA typing and by reverse transcription-PCR (RT-PCR) on RNA extracted from tumor samples. Each MAGE-A gene can be identified by specific amplification with pairs of primers unique for each sequence, which generates amplicons of different sizes that are visualized in agarose gels (2 ) . This method is robust but labor-intensive because separate PCR assays using different pairs of primers and annealing temperatures are required to detect the presence of the various MAGE-A mRNAs. Recently, a RT-PCR electrochemiluminescence assay was developed to detect MAGE-A-positive metastatic cancers in tissues and blood (19 ) . This assay seems to be very sensitive, but it does not allow identification of the various MAGE-A members that are expressed in the sample.
The emerging technology of DNA microarrays is especially useful for multiparametric detection, such as discrimination between the 12 MAGE-A sequences. The array is composed of a series of discrete regions bearing capture nucleotide probes that are able to hybridize complementary target nucleotide sequences. If the latter are labeled, a signal can be detected and measured at the hybridization site; its intensity should be proportional to the amount of target sequences present in the sample. However, such a multiparametric detection system may be difficult to optimize because the hybridization rate and the stability of hybrids in washing conditions are dependent on the sizes and nucleotide sequences of the various targets and probes that are incubated together. Homology between target sequences, as is the case with the MAGE-A genes, increases the difficulty because several targets may compete for the same capture probes.
In this study, we designed a post-PCR low-density microarray assay to analyze the expression of the 12 MAGE-A genes. The assay involved reverse transcription of total RNA with oligo(dT) primer, PCR amplification in the presence of Biotin-16-dUTP, and hybridization of the resulting PCR products on a DNA microarray (Fig. 1) . We assessed the specificity and the detection limits of the assay and performed a method comparison study on 32 RNA samples obtained from healthy tissues, tumor tissues, and tumor cell lines. detection of mage-a cDNA sequences with specific primers RNA extraction and RT-PCR amplifications were performed as described previously (2 ) with slight modifications. Briefly, total cellular RNA from melanoma tissues and cell lines was extracted by the guanidine isothiocyanate-cesium chloride procedure (24 ) , whereas samples from nonmelanoma tissues and cell lines were prepared with TriPure reagent (Roche). cDNA was synthesized from 2 g of total RNA by extension with oligo(dT) primer and 200 U of Moloney murine leukemia virus reverse transcriptase (Life Technologies) at 42°C for 90 min. PCR amplification was performed on 2.5 L (1/40) of the cDNA solution with 0.625 U of Taq DNA polymerase (Takara), 0.4 mol/L each primer, and 100 mol/L each dNTP (Takara) in a final volume of 25 L. Pairs of specific primers and amplification programs for each of the MAGE-A genes were as described by De Plaen et al.
Materials and Methods
(2 ) (for MAGE-A5, -A7, -A8, -A9, -A11) and van Baren et al. (25 ) . These primers were chosen in different exons to avoid the occasional false positives caused by DNA contamination of the RNA preparations. Thirty cycles of amplification were performed, except for MAGE-A5, -A7, -A8, -A9, -A11, and -A12 cDNA sequences, which were amplified for 32 cycles. After amplification, PCR products (10 L) were electrophoresed in 1.3% agarose gels and visualized by ethidium bromide fluorescence.
detection of mage-a cDNA sequences with consensus primers and hybridization on microarray cDNA was synthesized as described above. Primers for PCR amplification were DPSCONS2 (5Ј-GGGCTCCAG-CAGCCAAGAAGAGGA-3Ј, sense primer) and DPAS-CONB4 (5Ј-CGGTACTCCAGGTAGTTTTCCTGC-3Ј, antisense primer), which were derived from a consensus sequence for the last exon of the MAGE-A genes. They were used together with specific sense primers DPS-MAGE1 (5Ј-GGGTTCCAGCAGCCGTGAAGAGGA-3Ј), DPSMAGE8 (5Ј-GGGTTCCAGCAGCAATGAAGAGGA-3Ј), and DPSMAGE12 (5Ј-GGGCTCCAGCAACGAA-GAACAGGA-3Ј) to improve the amplification efficiencies of the MAGE-A1, -A8, and -A12 cDNAs. The size of the PCR products was ϳ540 bp. Amplification was per- (26 ) . Cycling was performed in a PTC-200 thermocycler (Biozym). PCR reactions were heated to 95°C for 5 min. Amplification was then carried out for 30 cycles (30 s at 94°C, 30 s at 55°C, 30 s at 72°C), and a final extension was performed at 72°C for 10 min. These conditions were chosen after an optimization study using recombinant plasmids containing MAGE-A1, -A2, MAGE DNA microarrays used the technology developed by Advanced Array Technology (AAT). They contained capture probes specific for each of the 12 MAGE-A sequences. Each probe was spotted on the array in quadruplicate. The spots were 400 m in diameter, and the distance between two adjacent spots was 600 m. The characteristics of the 12 capture probes are given in Tables  1 and 2 . Each microarray had two types of control spots. Detection control spots were biotinylated DNA to check the reliability of the detection step. Positive and negative hybridization control spots were capture probes that were allowed to react with biotinylated complementary or noncomplementary target sequences to check the specificity of the hybridization. The array included an additional negative control, which was the MAGE-A7 capture probe. Indeed, because MAGE-A7 is a pseudogene, no signal should be observed for that probe unless the mRNA has been contaminated by genomic DNA.
Microarrays were used as recommended by the manufacturer. The completed PCR reaction (15 L) was mixed with 55 L of hybridization solution (AAT) containing 5 nmol/L biotinylated DNA control; the mixture was then loaded on the array framed by an hybridization chamber (MJ Research Inc.). The chamber was closed with a coverslip. Slides were incubated at 65°C for 2 h and then washed four times for 2 min each with washing buffer (AAT).
Detection was by either fluorescence or colorimetry. Both detection methods have the same detection limits (27 ) . For fluorescence detection, slides were incubated for 45 min at room temperature with streptavidin labeled with cyanin-5 (Sigma) at 2 mg/L in blocking buffer (AAT). After incubation, slides were washed five times (2 A5a  A6  A7  A8  A9  A10  A11  A12   MAGE-A1  100  59  70  70  67  67  41  48  41  41  44  63  MAGE-A2  59  100  81  59  63  78  33  44  33  37  44  78  MAGE-A3  70  74  100  70  74  96  59  67  67  63  70  89  MAGE-A4  70  67  70  100  85  67  37  48  41  15  37  63  MAGE-A5  67  74  81  81  100  85  30  41  33  15  26  70  MAGE-A6  92  92  88  88  85  100  70  88  74  78  81  92  MAGE-A7  52  48  55  48  48  55  100  70  63  37  52  44  MAGE-A8  52  48  55  48  48  52  70  100  74  48  59  48  MAGE-A9  48  41  52  44  44  48  63  74  100  33  48  48  MAGE-A10  37  48  48  55  48  52  44  44  37  100  67  44  MAGE-A11  44  48  48  55  48  44  52  55  48  67  100  41  MAGE-A12  63  74  78  63  67  78  59  70  74  33  52  100 a The percentages of nucleotide identity are given.
min each) with washing buffer, rinsed twice with water, dried at 50°C for 15 min, and read with a GMS 418 array scanner (Genetic Microsystem). For colorimetric detection, slides were incubated for 45 min at room temperature with streptavidin labeled with colloidal gold (Sigma) diluted 1:1000 in blocking buffer. After incubation, slides were washed five times (2 min each) with washing buffer, rinsed twice with water, incubated for 15 min at room temperature with Silver Blue revelation solution (AAT), rinsed with water, dried, and read with a microarray colorimetric reader (AAT). The image of each array was analyzed with software from AAT. Briefly, this software uses three detection control spots as a reference and assigns a correlation coefficient between 0 and 1 to each of the other spots in the array. All analyses were done with the detection cutoff fixed to a correlation coefficient of 0.23. Signals below this value were considered as negative.
Results

specificity of the assay
To check the specificity of the assay, recombinant plasmids containing cDNA of MAGE-A1, -A2, -A3, -A4, -A5, -A6, -A8, -A9, -A10, -A11, or -A12 were subjected to PCR amplification with consensus primers DPSCONS2 and DPASCONB4. Analysis of PCR products by gel electrophoresis showed that the optimized PCR conditions described in Materials and Methods allowed us to amplify each of the 11 cDNA templates with high efficiency. The PCR products were hybridized on microarrays. Hybridization was specific except for the MAGE-A6 amplicons, which cross-hybridized on the MAGE-A3 capture probe (Fig. 2 and data not shown) . The reason for this crosshybridization was the 96% identity shared by these sequences (Table 2 ). Different hybridization conditions were then tested by varying the amplicon concentration, the incubation temperature, and the buffer composition. Although still present, the nonspecific signal from the MAGE-A3 capture probe was considerably reduced when a 5-L volume of biotinylated amplicons at 3.5 mg/L was incubated at 65°C for 2 h with the capture probes in the buffer provided by AAT. As shown in Fig. 2 , these conditions were used to hybridize PCR products amplified from 5 ng of recombinant plasmid containing MAGE -A1, -A2, -A3, -A4, -A5, -A6, -A8, -A9, -A10, -A11 , or -A12 cDNA on microarrays carrying four replicates of the 12 capture probes. Each hybridization was specific, except for a slight hybridization of the MAGE-A6 amplicons with the MAGE-A3 capture probe. This cross-reaction represented only 5% of the specific signal obtained with MAGE-A6 amplicons on the MAGE-A6 capture probe (data not shown). No cross-reaction was observed between the MAGE-A3 amplicon and the MAGE-A6 capture probe, whose sequences share only 88% identity ( Table 2 ).
detection limit of the assay
To estimate the detection limit of the microarray assay, various amounts of total RNA extracted from MZ2-MEL cells were tested. This melanoma line expresses MAGE-A1, -A2, -A3, -A6, and -A10 and weakly expresses MAGE-A5 and -A12 (2, 11 ) . RNA (2.0, 0.2, or 0.02 g) was reverse-transcribed with oligo(dT), and 1/40 of each cDNA reaction was PCR-amplified for 30 cycles with consensus primers DPSCONS2 and DPASCONB4. Portions of the PCR reactions ranging from 25 to 5 L were hybridized on microarrays under optimal conditions. When we used 2 g of RNA and either 25 or 15 L of the amplification reaction, the assay detected the expected MAGE-A genes, except MAGE-A12 (Table 3) . With Ͻ15 L of the amplification reaction or Ͻ2 g of RNA, some of the MAGE-A genes expressed in MZ2-MEL were not detected.
The failure of the microarray assay to detect MAGE-A12 expression in MZ2-MEL cells was probably the consequence of inefficient PCR amplification because of the three mismatches present in the consensus primer DPSCONS2 vs the sequence of MAGE-A12, including a destabilizing mismatch close to the 3Ј end (Fig. 1) . The MAGE-A genes whose expression in MZ2-MEL cells was readily detected with the microarray have only one (MAGE-A2 and -A5), two (MAGE-A3, -A6, and -A10), or three mismatches (MAGE-A1) that are less destabilizing. Thus, it was likely that the various MAGE-A cDNAs were not amplified with the same efficiency in the PCR performed with the selected consensus primers. We therefore supplemented the PCR mixture with specific sense primers corresponding to the less-matching MAGE-A sequences. By including sense primers specific for MAGE-A1, MAGE-A8, and MAGE-A12, the microarray assay could detect the expected MAGE-A genes in MZ2-MEL, including MAGE-A12 (data not shown). This method was also tested on melanoma cell line LB1751-MEL, which expresses
MAGE-A1, -A2, -A3, -A4, -A6, and -A10 and weakly expresses MAGE-A5, -A8, -A11, and -A12.
Two parallel assays were run: one without and the other with the three additional sense primers. With these specific primers added, hybridization of the resulting PCR products on the microarray allowed the detection of all expected MAGE-A genes except MAGE-A11. In the absence of specific primers (i.e., 1 mol/L each consensus primer), MAGE-A8 and -A12 were not detected, nor was MAGE-A11 (data not shown). The lack of detection of MAGE-A11 by the microarray was probably a consequence of inefficient PCR amplification caused by three mismatches in the sequence of consensus primer DPS-CONS2 vs the sequence of MAGE-A11 (Fig. 1) .
method comparison studies with cell lines and tissues
To validate the assay, a series of 32 oligo(dT)-primed cDNA samples from different tumor cell lines, tumor tissues, and healthy tissues was analyzed. Four independent PCRs were performed on each sample, and the resulting products were hybridized on separate microarrays. The pattern of MAGE-A gene expression in each sample was deduced from the signals detected in 4 ϫ 4 replicates of the 12 capture probes, as explained in the legend of Fig. 3 . Table 4 summarizes the results obtained with the microarray assay and with the semiquantitative PCR assays performed with specific primers generating amplicons of different sizes that were visualized in agarose gels. Virtually identical results were obtained with both methods, except for MAGE-A3 and MAGE-A5.
MAGE-A3 was detected in sample LB1781 by the microarray assay, but not by PCR with specific primers. The cloned PCR products obtained from this sample were sequenced, and MAGE-A6 sequences, but no MAGE-A3 sequences, were found. This indicated that false positives in the microarray assay resulted from a cross-hybridiza- tion of MAGE-A6 amplicons on the MAGE-A3 capture probe, as was observed previously with amplicons obtained from a MAGE-A6 cDNA cloned in a plasmid (see Fig. 2 ). To confirm these results, we analyzed seven additional samples that had been found positive for MAGE-A6 and negative for MAGE-A3 by PCR with specific primers; these samples were also positive for MAGE-A3 in the microarray assay. Therefore, when positive signals are observed simultaneously on the MAGE-A3 and MAGE-A6 probes, the expression of MAGE-A3 must be confirmed by PCR with specific primers. The microarray assay detected MAGE-A5 in eight samples in which expression of MAGE-A5 was not detected by PCR with specific primers. The sequence of the MAGE-A5 capture probe shares at most 85% identity with the other MAGE-A sequences (Table 2) . It was therefore unlikely that positive MAGE-A5 signals on the microarrays resulted from cross-hybridizations. A more probable explanation for this discrepancy was a lower detection limit of the hybridization assay for MAGE-A5 amplicons. In line with this explanation, three of the eight samples positive for MAGE-A5 in the arrays but negative by PCR with specific primers were found positive when the PCR was carried out for 35 cycles instead of 32 (Table 4) .
For the other MAGE-A genes, discrepancies between the results of the microarray assay and those of the comparison method were observed only in samples showing signals close to the detection limit with one or the other method. In 10 of 31 cases, the microarray assay failed to detect low MAGE-A expression (i.e., Ͻ10% of the expression found in the reference cell line, as assessed by PCR with specific primers; Table 4 ). Conversely, in four cases, low expression of MAGE-A2, -A9, or -A12 was detected with the microarray assay but not by PCR with specific primers. These discrepancies seem to be independent of the origin of the tested sample (tumor cell line or tissue).
Six tissue samples from healthy adults were analyzed. In agreement with previous reports (2, 10 ), each MAGE-A gene except the MAGE-A7 pseudogene was found to be expressed in testis, and none of these genes was expressed in the other healthy tissues tested (Table 4) .
Discussion
The assay presented here can be considered an easy screening test to identify the MAGE-A genes expressed in a tumor sample to determine which MAGE antigens could be used for immunization. The test is very fast and avoids the use of hazardous compounds such as ethidium bromide. Because a single capture probe is used for each MAGE-A gene, the cost of the assay is reduced and the interpretation of the data is straightforward, unlike highdensity microarrays, which rely on a pattern of hybridization to identify one target (28 ) . The whole assay, including PCR and hybridization on a microarray, was repeated four times for each of 32 cDNA samples from different tumor cell lines, tumor tissues, and healthy tissues to ascertain its reproducibility. A good correlation was found with the preexisting, well-established method of detection, which used one pair of primers for each MAGE-A sequence.
The capture probes for discrimination between the 12 MAGE-A cDNAs were chosen to have the same length (27 bases) and the greatest possible number of mismatches between the sequence of each MAGE-A gene and the sequences of the other genes of the family. Hybrids of the selected probes (27 bases) and the complementary se- Fig. 3 . Microarray display and data analysis for sample LB1751.
The assay conditions were as described in Materials and Methods. The products of four independent PCRs were hybridized on separate arrays. Colorimetric detection was used. After scanning of the arrays, image analysis software was used to detect spots with signals above the threshold. The detected spots are framed (Ⅺ). An array was considered positive for a MAGE-A gene when at least three spots were detected and negative when fewer than three spots were detected. Gene expression was scored according to the number of positive arrays: ϩ, strong or moderate (four or three positive arrays); (ϩ), weak (two positive arrays); Ϫ, very weak (one positive array) or no expression detected (no positive array).
quence are quite stable because their melting temperatures (T m s) are between 72 and 87°C. These differences in T m do not greatly influence the yield of the hybridization performed at 65°C. This temperature is within the limits of 5-25°C below the T m s of the various probes, thus ensuring maximal hybridization rates (29 ) . The probes are fixed on the substrate by their ends through covalent bonds that are compatible with the high salt and temperature conditions used in the hybridization step; fixation by their ends allows better control of the length and sequence of the capture probe available for hybridization (30 ) . Probes of identical lengths have similar access to Gene expression was scored according to the number of positive microarrays as described in the legend for Fig. 3 : ϩ, strong or moderate; (ϩ), weak; Ϫ, very weak, or no expression detected. e Discrepancies "Ϫ/ϩ" are framed. f Sample was found to express MAGE-A5 when PCR with specific primers was carried out for 35 cycles instead of 32.
their complementary sequences fixed on the substrate. Because the probes are present in a large excess in comparison with the target molecules, reassociation kinetics are largely determined by the concentration of target molecules. These pseudo-first-order reaction conditions greatly improve quantitative evaluation by minimizing the effects of minor differences in capture probe concentration (30 ) . Although selected in regions that are highly conserved in the 12 MAGE-A sequences, the consensus primers were not able to amplify the various MAGE-A cDNAs with the same efficiency. It was necessary to add three specific primers to ensure the efficient amplification of each of the 12 MAGE-A sequences. The microarray assay could detect MAGE-A5, which is expressed in very small amounts in a tumor cell line such as MZ2-MEL, where the relative abundance of MAGE-A5 mRNA is as low as 1/500 000 (11 ) . For detection of the other MAGE-A genes, the microarray assay appeared to have higher detection limits than the comparison method. The latter allowed the detection of expression corresponding to Ͻ1% of the expression found in the reference cell line (data not shown), whereas for some samples the microarray assay failed to detect expression Ͻ10% of the reference cell lines (Table 4 ). An increased number of PCR cycles (e.g., 35 cycles instead of 30) would certainly improve the detection limit of the microarray assay, but as discussed below, this would also increase the risk of false positives resulting from amplification of contaminating genomic DNA sequences. Another possibility would be to modify the detection method by use of anti-biotin antibodies instead of streptavidin conjugates. Preliminary results indicate that this modification is likely to improve the detection limit of the microarray assay 10-to 100-fold. A 10-fold improvement should be sufficient because patients whose tumors express Ͻ3% of the amount found in the reference cell line are not included in protocols of immunization with MAGE antigens.
A drawback of the microarray assay is its inability to discriminate between MAGE-A6 and MAGE-A3 sequences, which differ by only one nucleotide. One possibility to avoid this cross-hybridization would be to dilute the amplicons, but this alternative would lead to weaker signals for other MAGE-A genes (data not shown). Another possibility would be to use shorter capture probes of 18 -20 bases, which are very discriminating because, in that case, the presence of only one mismatch lowers the melting temperature of the probe by as much as 5°C (31 ). Short capture probes are used to detect single-nucleotide polymorphisms (32, 33 ) . Another original approach for the detection of single-nucleotide polymorphisms is the insertion of nucleotide analogs known as locked nucleic acid monomers in the probe to increase the thermal stability of the perfect matches vs mismatches (34 ) . The applicability of these approaches to improve discrimination between MAGE-A3 and -A6 needs to be investigated.
The microarray assay does not distinguish between PCR products amplified from mRNA and those amplified from genomic DNA because primers were chosen in the same exon of the MAGE-A genes. This may lead to false-positive results if genomic DNA sequences present in the sample as contaminants are amplified. However, because MAGE-A7 is a pseudogene, no signal should be observed with the MAGE-A7 capture probe unless genomic DNA sequences were amplified. In this study, no signal for that capture probe was observed in any sample (Table 4) . To confirm the absence of DNA contamination, a mock RT-PCR was performed on each of the 32 RNA samples (omitting the reverse transcriptase in the reverse transcription step), and PCR products were hybridized on microarrays carrying the 12 MAGE-A capture probes. No signal was detected in any sample (data not shown).
In conclusion, we have shown that low-density microarrays can be a good discriminating tool for detecting homologous sequences amplified by consensus primers.
The microarray assay described here should facilitate tumor diagnosis related to therapeutic vaccinations involving MAGE-A gene products. This approach is also suitable for sensitive identification of different Staphylococcus species (35 ) .
